The healthiest cookies you’ll choose today

Our website uses cookies to collect useful information that lets us and our partners support basic functionality, analyze visitor traffic, deliver a better user experience, and provide ads tailored to your interests. Agreeing to the use of cookies is your choice. Learn more

Decline cookies Accept cookies
Skip to content
Fullscript leaf logo Sign in
Fullscript logo
Fullscript leaf logo
  • Our platform
    • Practitioner software
    • Pricing
    • Integrations
    • Patients on Fullscript
    • Book a demo
  • Learn
    • Spotlight
    • Protocols
    • Wellness blog
    • Practice resources
    • Webinars
    • Ingredient library
    • Practicing virtually
  • Support
    • Practitioner support
    • Patient help
    • Contact us
    • Or chat with us
Sign in Create account
Conditions
—

SIBO: What the Science Says

November 26, 2020
Fact checked
Written by Kayla Robinson, BKin, RHN
Medically reviewed by
Dr. Alex Keller, ND
  1. Wellness blog
  2. SIBO: What the Science Says

If you suffer from chronic gastrointestinal issues such as diarrhea, abdominal pain, and bloating, you may have a bacterial imbalance in your gut. Small intestinal bacterial overgrowth, commonly referred to by its acronym SIBO, has gained attention in recent years as a potential cause of many gastrointestinal complaints. Although poorly understood, emerging research has provided some insight into the best treatment approaches for SIBO. (4)

Continue reading to learn the signs, symptoms, and common causes of SIBO, as well as how to address this condition.

What is SIBO?

SIBO is a chronic intestinal disorder characterized by excessive amounts of bacteria in the small intestine. Under normal conditions, the upper small intestine contains less than 103 organisms/mL, primarily composed of Gram-positive bacteria. (4) In cases of SIBO, the bacterial population in an individual’s small intestine, specifically within the proximal jejunum, exceeds 105–106 organisms/mL. (1)(4)

Bacterial dysbiosis related to SIBO may contribute to epithelial tight junction dysfunction and increased intestinal permeability, resulting in permeation of endotoxins and production of proinflammatory cytokines. (3)

A doctor examining a patient's stomach
SIBO is a digestive condition characterized by excessive amounts of bacteria in the small intestine.

Signs and symptoms

Symptoms of SIBO, which may vary between individuals, (4) are non-specific and often overlap with a number of other associated disorders, making it difficult to determine the true prevalence of the condition. (4)(8) It has also been suggested that the extent of mucosal inflammation, the degree of overgrowth, and composition of microbes found in the small intestine play a significant role in the severity and type of symptoms experienced. SIBO typically presents with fatigue, weakness, (4) and a number of gastrointestinal symptoms, such as abdominal pain, abdominal distension, bloating, flatulence, and chronic diarrhea. (1)(4)

SIBO may also result in malabsorption of micro- and macronutrients, nutrient deficiencies (e.g., fat-soluble vitamins, vitamin B12, iron), (1)(4) and other complications. Complications and extraintestinal manifestations of SIBO may include:

  • Anemia
  • Arthralgia (joint pain)
  • Chronic prostatitis
  • Hypoproteinemia/hypoalbuminemia (4)
  • Interstitial cystitis
  • Neuropathies (3)(4)
  • Osteoporosis
  • Restless legs syndrome
  • Rosacea
  • Steatorrhea
  • Weight loss (3)

Causes and risk factors

The development of SIBO can be attributed to a disruption in the homeostatic mechanisms regulating commensal intestinal microflora. Inadequate gastric secretion (hypochlorhydria) and small intestine dysmotility are the two most common factors that predispose individuals to bacterial overgrowth. (4)

Other factors that have been shown to increase an individual’s susceptibility to SIBO include:

  • Age, resulting in an increased risk in the elderly population (4)
  • Alcoholism (3)
  • Anatomic alterations or abnormalities of the GI tract, such as diverticula, strictures, fistulas, surgical loupes, and gastric or ileocecal valve resection
  • Certain medications, such as antibiotics, proton pump inhibitors, and antimotility agents (3)(4)
  • Certain metabolic conditions, such as diabetes (enteropathy) and hypochlorhydria (4)
  • Dysfunction of certain organs, such as cirrhosis, renal failure, pancreatitis, scleroderma and Crohn’s disease
  • Impairment of systemic and local immunity, including immunodeficiency states (1)(3)(4)
  • Irritable bowel syndrome (IBS)
  • Motility disorders, such as small intestine dysmotility, celiac disease, and gastroparesis (1)(4)
  • Vagotomy, surgical alteration or partial removal of the vagus nerve (3)

Intake of carbohydrates, such as fructose, lactose, and fermentable oligo-, di-, monosaccharides and polyols (FODMAPs), fiber, prebiotics, and probiotics have also been shown to alter the intestinal microbiota and may, therefore, increase the risk of developing SIBO or exacerbate its symptoms. (3)

Learn more about causes, symptoms, diagnosis, and dietary supplement interventions for SIBO.

Addressing SIBO: Diagnostic methods

While SIBO is often difficult to recognize due to its non-specific symptoms, certain laboratory tests have improved our ability to diagnose the condition. (4) Common diagnostic tests available for SIBO include bacterial cultures, which involve collecting information on anaerobic and aerobic colony counts in the small intestine, and hydrogen breath tests. Due to challenges with bacterial cultures, hydrogen breath tests for various substrates, such as lactulose, glucose, lactose, and fructose, have become the predominantly used testing method. (3)(4)(5)

Addressing SIBO: Treatment methods

Currently, the treatment strategy for SIBO typically involves identifying and addressing the underlying cause, treating the overgrowth of bacteria and associated symptoms, and correcting nutrient deficiencies. (1) In addition to identifying the underlying cause and correcting nutritional deficiencies, an integrative approach to SIBO treatment may utilize antimicrobials to address bacterial overgrowth and incorporate dietary interventions. (4)

Identify the underlying cause

As previously outlined, there are a number of possible factors that may contribute to the development of SIBO, such as structural, anatomical, or functional abnormalities of the gastrointestinal tract, several health conditions (e.g., IBS, motility and metabolic disorders), impaired immunity, and certain medications. (4) Identifying the underlying cause of the overgrowth will inform and impact the optimal approach to treatment.

Bowls of beans including lentils, nuts and seeds on top of a cutting board
A low-FODMAP diet may be beneficial as intake of these foods has been identified as a possible factor contributing to the development of SIBO.

Follow a SIBO diet

In cases of SIBO, FODMAPs may be fermented by bacteria in the small intestine leading to digestive symptoms commonly associated with the condition, including abdominal pain, bloating, and flatulence. It has been theorized that these symptoms may be improved by restricting carbohydrate intake. (6) Therapeutic diets that limit carbohydrate intake, such as the low-FODMAP diet, the Specific Carbohydrate Diet (SCD), and the Gut and Psychology Syndrome (GAPS) diet, have been proposed as a method to eradicate SIBO. While these diets may be beneficial in some patients, limited evidence examining their effectiveness is currently available. (7)

In severe cases of SIBO, a liquid elemental diet (ED) may be considered. First used for treating wasting syndromes and gastrointestinal disorders such as Crohn’s disease and eosinophilic esophagitis, the elemental diet consists of water and an easily absorbed elemental formula typically composed of amino acids, medium-chain triglycerides, simple carbohydrates, sugars, and essential vitamins and minerals. It has been hypothesized that the mechanism by which this diet targets SIBO involves starving small intestinal bacteria by restricting carbohydrate intake and facilitating healing of the GI tract. However, further research is necessary to fully understand the mechanism of action for the ED. (7)

Furthermore, while the ED meets energy requirements and provides all necessary nutrients, compliance may be low due to feelings of dietary restriction, taste, blood sugar dysregulation, and certain digestive symptoms (e.g., constipation). (7)

Correct nutrient deficiencies

SIBO may lead to damage to the small intestinal mucosa and microvilli, resulting in malabsorption of nutrients in the intestinal lumen and nutrient deficiencies. The most common nutrient deficiencies reported in individuals with SIBO include calcium, magnesium, vitamin B12, and fat-soluble vitamins A, D, E, and K. Nutrient deficiencies, which can range from mild to severe, should be addressed with supplementation as necessary. (4)

Address the overgrowth

Antibiotics, such as rifaximin, are most commonly used to treat overgrowth with varying success, (1)(3) however, long-term or frequent use of antibiotics can be costly and may induce adverse effects on the intestinal microbiome. It has been suggested that herbal antimicrobials may be an effective treatment option for bacterial overgrowth. A number of herbs have demonstrated antimicrobial activity, such as oil of oregano, wormwood, Coptis root, thyme, red thyme, field horsetail, olive leaf, and berberine extracts. (3)

Certain herbal antimicrobials, such as oil of oregano, have been shown to be as effective as antibiotic treatment. One four-week study examined the effects of rifaximin compared to herbal therapy in 104 patients with SIBO, diagnosed by a lactulose breath test (LBT). Patients were given a dose of rifaximin three times daily or two capsules of commercial herbal preparations twice daily.

Following treatment with antibiotic or herbal regimens, another lactulose breath test (LBT) was conducted to determine the effects of the intervention. Results demonstrated that 46% of individuals receiving the herbal therapy and 34% of individuals receiving rifaximin had negative follow-up LBTs, indicating similar effectiveness of antibiotic and herbal therapies in SIBO treatment.

Furthermore, patients who did not respond to antibiotic treatment were offered an herbal rescue therapy or triple antibiotics. Similarly, comparable response rates were observed between individuals receiving antibiotics (60%) and those receiving the herbal intervention (57.1%). (3)

Focus on prevention of recurrence

Prevention of recurrence is essential as relapse rates following SIBO treatment are high. In one study, the recurrence of SIBO following successful rifaximin treatment was found to be 44%. (2) Correcting underlying conditions and minimizing risk factors related to SIBO can help prevent recurrence. (7) Additionally, a number of protective factors that may reduce the risk of developing SIBO have been identified, including:

  • Augmentation of the migrating motor complex (MMC)
  • Biofilm disruption
  • Gastric acid, pancreatic enzyme, and bile acid supplementation
  • Intestinal motility training
  • Sufficient secretory immunoglobulin A (3)

The bottom line

An integrative approach to SIBO treatment should involve identifying any underlying causes, treating the bacterial overgrowth, correcting nutrient deficiencies, and preventing recurrence. The conventional approach to bacterial overgrowth eradication typically involves the use of pharmaceutical antibiotics, however, herbal antimicrobials and several carbohydrate-restricting diets have also been proposed as therapeutic interventions. While preliminary evidence suggests that herbal antimicrobials may be as effective as antibiotics, further research is needed to clearly identify effective ingredients and dosing. If you’re a patient, speak to your integrative healthcare practitioner for treatment recommendations.

Fullscript simplifies supplement dispensing

Create your dispensary today I'm a patient
References
  1. Bohm, M., Siwiec, R.M., & Wo, J.M. (2013). Diagnosis and management of small intestinal bacterial overgrowth. Nutrition in Clinical Practice, 28(3), 289-99.
  2. Bures, J., Cyrany, J., Kohoutova, D., Förstl, M., Rejchrt, S., Kvetina, J., … Kopacova, M. (2010). Small intestinal bacterial overgrowth syndrome. World Journal of Gastroenterology, 16(24), 2978–2990.
  3. Chedid, V., Dhalla, S., Clarke, J. O., Roland, B. C., Dunbar, K. B., Koh, J., … Mullin, G. E. (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Global Advances in Health and Medicine, 3(3), 16–24.
  4. Dukowicz, A. C., Lacy, B. E., & Levine, G. M. (2007). Small intestinal bacterial overgrowth: A comprehensive review. Gastroenterology & Hepatology, 3(2), 112–122.
  5. Ghoshal U. C. (2011). How to interpret hydrogen breath tests. Journal of Neurogastroenterology and Motility, 17(3), 312–317.
  6. Ghoshal, U. C., Shukla, R., & Ghoshal, U. (2017). Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy. Gut and Liver, 11(2), 196–208.
  7. Mary Ann Liebert, Inc. (2018). Clinical roundup: Selected treatment options for small intestinal bacterial overgrowth. Alternative and Complementary Therapies, 24(3).
  8. Sachdev, A. H., & Pimentel, M. (2013). Gastrointestinal bacterial overgrowth: Pathogenesis and clinical significance. Therapeutic Advances in Chronic Disease, 4(5), 223–231.

  • Print
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • Pinterest

Disclaimer

The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Cancel reply

Your email address will not be published. Required fields are marked *

Prev Next
Back to main wellness blog page

Get more resources for your practice

Protocols
Practice resources
Ingredient library
Webinars

Share

  • Print
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • Pinterest

Fullscript content philosophy

At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.

Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:

  1. In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
  2. Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
  3. A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
  4. Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
  5. All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
  6. Potential conflicts of interest are clearly disclosed.
Read more
Fullscript logo

We're certified carbon-neutral. It's part of our commitment to helping people get better.

American flag - toggles to show american specific contentUnited States
Canadian flag - toggles to show canada specific contentCanada
Product
  • Practitioner software
  • Integrations
  • Pricing
  • Patients
  • Supplement quality
  • Treatment adherence
  • Catalog
  • Wholesale
Company
  • Spotlight
  • About Fullscript
  • Collective
  • Leadership
  • Culture guide
  • Careers
  • Engineering
  • News
Support
  • Practitioner support
  • Patient help
  • Testimonials
  • General FAQ
  • Patient shipping
  • Wholesale shipping

© Fullscript 2023. All rights reserved.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

  • Privacy Statement
  • Terms of Service
  • Accessibility Policy
  • Customer Support Policy
  • Acceptable Use Policy
  • California Privacy Notice
Send this to a friend